ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Food

Nestlé under fire in India for clinical research on preterm babies

by K. V. Venkatasubramanian, special to C&EN
August 11, 2019 | APPEARED IN VOLUME 97, ISSUE 32

 

India is probing whether Swiss food giant Nestlé, whose products include infant formula and baby food, illegally funded a clinical trial involving preterm infants. India’s Infant Milk Substitutes, Feeding Bottles, and Infant Foods Act bans producers, suppliers, or distributors of infant milk substitutes from funding seminars, conferences, educational courses, fellowships, or research. The Breastfeeding Promotion Network of India, an advocacy group, found the clinical trial listed in a government registry. The registry lists Nestlé India as the primary sponsor of the trial, which was to monitor 75 infants born at 24–34 weeks’ gestation “to assess the growth outcomes and feeding intolerance observed” in the infants. “Nestlé India is always in compliance with all laws and regulations,” and the study was approved by the ethics committees of the trial sites, a company spokesperson says. The objective of the study in question was to encourage science-based research, not to promote the use of infant milk substitutes, feeding bottles, or infant foods, the spokesperson says. The Indian Council of Medical Research is investigating whether the study violated the law. Nestlé was also in the spotlight in January for allegedly influencing doctors to recommend its baby products, including infant milk powder, to parents.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment